Posted by Michael Wonder on 11 Aug 2021
Turning Point Therapeutics granted sixth regulatory designation for repotrectinib
11 August 2021 - Fast track designation granted by FDA in ROS1 positive advanced non-small-cell lung cancer patients pretreated with one prior ROS1 tyrosine kinase inhibitor without prior chemotherapy.
Turning Point Therapeutics today announced the U.S. FDA granted a sixth regulatory designation to lead drug candidate, repotrectinib.
The fast track designation was granted for the treatment of patients with ROS1 positive advanced non-small cell lung cancer who have been previously treated with one prior ROS1 tyrosine kinase inhibitor and who have not received prior platinum-based chemotherapy.
